• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Let the Biologics Begin

Article

The FDA's Jan. 31 approval of Amevive (alefacept) for chronic plaque psoriasis represents the first step down an exciting new road, said Alan Menter, M.D, medical director of the Psoriasis Research Center at Baylor University Medical Center.

Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
Sanofi Reports High Efficacy in Dupilumab for BP

Sanofi Reports High Efficacy in Dupilumab for BP

Article
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Podcast
Research Highlights Disparities in Melanoma Knowledge and Care

Research Highlights Disparities in Melanoma Knowledge and Care

Article
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Podcast
Nearly half of FDA-authorized AI tools may be ineffective

Nearly half of FDA-authorized AI tools may be ineffective

Article
CG and Minoxidil Combination Therapy Shows Promise for AA

CG and Minoxidil Combination Therapy Shows Promise for AA

Article
© 2024 MJH Life Sciences

All rights reserved.